JANX
Janux Therapeutics, Inc.
Price Chart
Latest Quote
$18.22
+0.19 (+1.05%)
Current Price
| Previous Close | $18.03 |
| Open | $17.89 |
| Day High | $18.39 |
| Day Low | $17.66 |
| Volume | 712,588 |
Stock Information
| Shares Outstanding | 61.14M |
| Total Debt | $20.99M |
| Cash Equivalents | $970.91M |
| Revenue | $24.00M |
| Net Income | $-102.59M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | $1.11B |
| EPS (TTM) | $-1.64 |
| Exchange | NGM |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $163.99M |
| Sales | $24.00M |
| Income | $-102.59M |
| Book/sh | $15.19 |
| Cash/sh | $15.88 |
| Employees | 113 |
Financial Ratios
| Quick Ratio | 16.25 |
| Current Ratio | 16.35 |
| Debt/Eq | 2.26 |
Returns & Margins
| ROA | -8.80% |
| ROE | -10.70% |
| Operating Margin | -308.66% |
Ownership
| Insider Ownership | 1.49% |
| Institutional Ownership | 101.41% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| Forward P/E | -6.94 |
| P/S | 46.41 |
| P/B | 1.20 |
Analyst Data
| Recommendation | strong_buy |
| Target Price | $36.24 |
Technical Indicators
| SMA20 | $17.11 |
| SMA50 | $16.17 |
| SMA200 | $15.76 |
| RSI | 66.22 |
| ATR | 0.6875 |
| Shares Float | 42.53M |
| Short Float | 13.88% |
| Short Ratio | 9.28 |
| Volatility | 2.51 |
| Rel Volume | 1.00 |
Performance History
| Week | +4.77% |
| Month | +16.94% |
| Quarter | +24.88% |
| 6 Months | +33.87% |
| YTD | +33.48% |
| Year | -21.97% |
| 3 Years | +57.07% |
| 5 Years | -35.91% |
| 10 Years | -27.55% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-08-31 | $18.22 | 712,600 |
| 2026-08-28 | $18.03 | 637,800 |
| 2026-08-27 | $18.78 | 577,300 |
| 2026-08-26 | $18.89 | 524,000 |
| 2026-08-25 | $18.68 | 1,074,400 |
| 2026-08-24 | $18.60 | 1,451,900 |
| 2026-08-21 | $17.39 | 520,000 |
| 2026-08-20 | $17.28 | 1,121,800 |
| 2026-08-19 | $17.52 | 914,200 |
| 2026-08-18 | $16.96 | 583,100 |
| 2026-08-17 | $16.26 | 540,800 |
| 2026-08-14 | $16.12 | 441,500 |
| 2026-08-13 | $16.00 | 847,400 |
| 2026-08-12 | $16.67 | 652,900 |
| 2026-08-11 | $16.52 | 577,900 |
| 2026-08-10 | $16.41 | 740,000 |
| 2026-08-07 | $15.85 | 689,000 |
| 2026-08-06 | $16.10 | 540,900 |
| 2026-08-05 | $16.00 | 546,000 |
| 2026-08-04 | $15.96 | 564,700 |
| 2026-08-03 | $15.32 | 558,900 |
About Janux Therapeutics, Inc.
Janux Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engager (TRACTr), Tumor Activated Immunomodulator (TRACIr), and Adaptive Immune Response Modulator (ARM) platforms technology to treat patients with cancer. The company's clinical candidates include JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor that is in Phase 1 clinical trial for the treatment of various solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, renal cell carcinoma, small cell lung cancer, pancreatic ductal adenocarcinoma, and triple-negative breast cancer. It also develops JANX011, a CD19-targeted adaptive immune response modulator that is in phase 1 clinical study developed for autoimmune diseases. The company has strategic research collaboration agreement with Merck Sharp & Dohme Corp. to develop TRACTr product candidates; and Bristol Myers Squibb to develop and commercialize an undisclosed, novel tumor-activated therapeutic targeting a validated solid tumor antigen expressed across several human cancer types. Janux Therapeutics, Inc. was incorporated in 2017 and is headquartered in San Diego, California.
đ° Latest News
Chipotle downgraded, Darden upgraded: Wall Street's top analyst calls
The Fly âĸ 2026-08-24T13:54:42Z
Here Are Mondayâs Top Wall Street Analyst Research Calls: AstraZeneca, Celestica, Chipotle Mexican Grill, Dominoâs Pizza, Fortune Brands, Golar LNG, Jersey Mikeâs Subs, Roku, and More
24/7 Wall St. âĸ 2026-08-24T11:49:22Z
Janux Therapeutics (JANX) Is Up 7.1% After Reporting Narrower Net Losses And Improved Earnings Profile
Simply Wall St. âĸ 2026-08-11T10:10:32Z
Janux Therapeutics, Inc. (JANX) Reports Q2 Loss, Lags Revenue Estimates
Zacks âĸ 2026-08-06T21:20:03Z
3 Small-Cap Biotech Stocks Pairing Rapid Revenue Growth With High Insider Ownership
Simply Wall St. âĸ 2026-07-24T05:56:54Z
Is Janux Therapeuticsâ (JANX) Russell Index Exit Quietly Rewriting Its Investor Base and Story?
Simply Wall St. âĸ 2026-07-09T09:10:44Z
VERAXA Biotech Stock in Focus as Lead Cancer Program Reaches Development Milestone
Exec Edge âĸ 2026-07-02T22:40:48Z
Is Janux Therapeutics, Inc. (JANX) Stock a Biotech Opportunity With Next-Generation Immunotherapy Potential?
Insider Monkey âĸ 2026-06-30T13:06:39Z
Akari Therapeutics Highlights 1st ASCO Abstract Acceptance
IPO-Edge.com âĸ 2026-05-28T22:33:46Z
VERAXA Biotech Secures $27.5M Financing, to Go Public Via SPAC
Exec Edge âĸ 2026-05-28T16:53:50Z
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Revenue | ||||
| Total Revenue | $10,000,000 | $10,588,000 | $8,083,000 | $8,612,000 |
| Operating Revenue | $10,000,000 | $10,588,000 | $8,083,000 | $8,612,000 |
| Expenses | ||||
| Total Expenses | $167,667,000 | $109,435,000 | $81,062,000 | $75,703,000 |
| Net Non Operating Interest Income Expense | $44,042,000 | $29,853,000 | $14,686,000 | $4,032,000 |
| Operating Expense | $167,667,000 | $109,435,000 | $81,062,000 | $75,703,000 |
| General And Administrative Expense | $41,771,000 | $41,047,000 | $26,140,000 | $22,262,000 |
| Interest Expense | - | - | - | - |
| Interest Expense Non Operating | - | - | - | - |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $-113,625,000 | $-68,994,000 | $-58,293,000 | $-63,059,000 |
| Net Interest Income | $44,042,000 | $29,853,000 | $14,686,000 | $4,032,000 |
| Interest Income | $44,042,000 | $29,853,000 | $14,686,000 | $4,032,000 |
| Normalized Income | $-113,625,000 | $-68,994,000 | $-58,293,000 | $-63,059,000 |
| Net Income From Continuing And Discontinued Operation | $-113,625,000 | $-68,994,000 | $-58,293,000 | $-63,059,000 |
| Total Operating Income As Reported | $-157,667,000 | $-98,847,000 | $-72,979,000 | $-67,091,000 |
| Net Income Common Stockholders | $-113,625,000 | $-68,994,000 | $-58,293,000 | $-63,059,000 |
| Net Income | $-113,625,000 | $-68,994,000 | $-58,293,000 | $-63,059,000 |
| Net Income Including Noncontrolling Interests | $-113,625,000 | $-68,994,000 | $-58,293,000 | $-63,059,000 |
| Net Income Continuous Operations | $-113,625,000 | $-68,994,000 | $-58,293,000 | $-63,059,000 |
| Pretax Income | $-113,625,000 | $-68,994,000 | $-58,293,000 | $-63,059,000 |
| Interest Income Non Operating | $44,042,000 | $29,853,000 | $14,686,000 | $4,032,000 |
| Operating Income | $-157,667,000 | $-98,847,000 | $-72,979,000 | $-67,091,000 |
| Per Share | ||||
| Diluted EPS | $-1.83 | $-1.28 | $-1.32 | $-1.52 |
| Basic EPS | $-1.83 | $-1.28 | $-1.32 | $-1.52 |
| Other | ||||
| Tax Effect Of Unusual Items | $0 | $0 | $0 | $0 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-155,638,000 | $-96,787,000 | $-71,024,000 | $-66,250,000 |
| Reconciled Depreciation | $2,029,000 | $2,060,000 | $1,955,000 | $841,000 |
| EBITDA (Bullshit earnings) | $-155,638,000 | $-96,787,000 | $-71,024,000 | $-66,250,000 |
| EBIT | $-157,667,000 | $-98,847,000 | $-72,979,000 | $-67,091,000 |
| Diluted Average Shares | $61,966,999 | $53,751,480 | $44,016,283 | $41,469,631 |
| Basic Average Shares | $61,966,999 | $53,751,480 | $44,016,283 | $41,469,631 |
| Diluted NI Availto Com Stockholders | $-113,625,000 | $-68,994,000 | $-58,293,000 | $-63,059,000 |
| Research And Development | $125,896,000 | $68,388,000 | $54,922,000 | $53,441,000 |
| Selling General And Administration | $41,771,000 | $41,047,000 | $26,140,000 | $22,262,000 |
| Other Gand A | $41,771,000 | $41,047,000 | $26,140,000 | $22,262,000 |
Fetched: 2026-08-31
Balance Sheet (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $956,822,000 | $1,022,781,000 | $344,349,000 | $320,740,000 |
| Total Assets | $1,001,565,000 | $1,061,516,000 | $380,407,000 | $364,010,000 |
| Total Non Current Assets | $25,678,000 | $27,850,000 | $31,166,000 | $31,571,000 |
| Other Non Current Assets | $3,424,000 | $3,700,000 | $3,325,000 | $2,206,000 |
| Current Assets | $975,887,000 | $1,033,666,000 | $349,241,000 | $332,439,000 |
| Prepaid Assets | $2,892,000 | $3,112,000 | $3,052,000 | - |
| Receivables | $6,428,000 | $5,381,000 | $2,161,000 | - |
| Accrued Interest Receivable | $6,428,000 | $5,381,000 | $2,161,000 | - |
| Cash Cash Equivalents And Short Term Investments | $966,567,000 | $1,025,173,000 | $344,028,000 | $327,016,000 |
| Cash And Cash Equivalents | $52,334,000 | $430,605,000 | $19,205,000 | $51,426,000 |
| Other Current Assets | - | - | $5,213,000 | $5,423,000 |
| Accounts Receivable | - | - | - | - |
| Debt | ||||
| Total Debt | $22,139,000 | $23,025,000 | $24,542,000 | $25,305,000 |
| Long Term Debt And Capital Lease Obligation | $19,746,000 | $21,276,000 | $23,025,000 | $24,542,000 |
| Current Debt And Capital Lease Obligation | $2,393,000 | $1,749,000 | $1,517,000 | $763,000 |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $44,743,000 | $38,735,000 | $36,058,000 | $43,270,000 |
| Total Non Current Liabilities Net Minority Interest | $19,746,000 | $21,276,000 | $23,025,000 | $26,763,000 |
| Current Liabilities | $24,997,000 | $17,459,000 | $13,033,000 | $16,507,000 |
| Payables And Accrued Expenses | $18,014,000 | $11,144,000 | $6,508,000 | $7,667,000 |
| Payables | $4,971,000 | $4,026,000 | $2,424,000 | $2,159,000 |
| Accounts Payable | $4,971,000 | $4,026,000 | $2,424,000 | $2,159,000 |
| Current Deferred Liabilities | - | $0 | $1,705,000 | $5,406,000 |
| Non Current Deferred Liabilities | - | - | $0 | $2,221,000 |
| Other Current Liabilities | - | - | - | $169,000 |
| Equity | ||||
| Common Stock Equity | $956,822,000 | $1,022,781,000 | $344,349,000 | $320,740,000 |
| Total Equity Gross Minority Interest | $956,822,000 | $1,022,781,000 | $344,349,000 | $320,740,000 |
| Stockholders Equity | $956,822,000 | $1,022,781,000 | $344,349,000 | $320,740,000 |
| Gains Losses Not Affecting Retained Earnings | $4,316,000 | $2,163,000 | $665,000 | $-1,535,000 |
| Other Equity Adjustments | $4,316,000 | $2,163,000 | $665,000 | $-1,535,000 |
| Retained Earnings | $-351,382,000 | $-237,757,000 | $-168,763,000 | $-110,470,000 |
| Preferred Securities Outside Stock Equity | - | - | - | - |
| Other | ||||
| Ordinary Shares Number | $60,384,283 | $59,064,606 | $46,252,440 | $41,616,260 |
| Share Issued | $60,384,283 | $59,064,606 | $46,252,440 | $41,616,260 |
| Tangible Book Value | $956,822,000 | $1,022,781,000 | $344,349,000 | $320,740,000 |
| Invested Capital | $956,822,000 | $1,022,781,000 | $344,349,000 | $320,740,000 |
| Working Capital | $950,890,000 | $1,016,207,000 | $336,208,000 | $315,932,000 |
| Capital Lease Obligations | $22,139,000 | $23,025,000 | $24,542,000 | $25,305,000 |
| Total Capitalization | $956,822,000 | $1,022,781,000 | $344,349,000 | $320,740,000 |
| Additional Paid In Capital | $1,303,828,000 | $1,258,316,000 | $512,401,000 | $432,703,000 |
| Capital Stock | $60,000 | $59,000 | $46,000 | $42,000 |
| Common Stock | $60,000 | $59,000 | $46,000 | $42,000 |
| Preferred Stock | $0 | $0 | $0 | $0 |
| Long Term Capital Lease Obligation | $19,746,000 | $21,276,000 | $23,025,000 | $24,542,000 |
| Current Capital Lease Obligation | $2,393,000 | $1,749,000 | $1,517,000 | $763,000 |
| Pensionand Other Post Retirement Benefit Plans Current | $4,590,000 | $4,566,000 | $3,303,000 | $2,671,000 |
| Current Accrued Expenses | $13,043,000 | $7,118,000 | $4,084,000 | $5,508,000 |
| Net PPE | $22,254,000 | $24,150,000 | $27,841,000 | $29,365,000 |
| Accumulated Depreciation | $-6,967,000 | $-4,952,000 | $-2,914,000 | $-972,000 |
| Gross PPE | $29,221,000 | $29,102,000 | $30,755,000 | $30,337,000 |
| Other Properties | $27,719,000 | $27,652,000 | $29,335,000 | $29,117,000 |
| Machinery Furniture Equipment | $1,502,000 | $1,450,000 | $1,420,000 | $1,075,000 |
| Other Short Term Investments | $914,233,000 | $594,568,000 | $324,823,000 | $275,590,000 |
| Current Deferred Revenue | - | $0 | $1,705,000 | $5,406,000 |
| Non Current Deferred Revenue | - | - | $0 | $2,221,000 |
| Construction In Progress | - | - | $43,000 | $145,000 |
| Treasury Shares Number | - | - | - | - |
Fetched: 2026-08-31
Cash Flow Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $-83,278,000 | $-44,173,000 | $-52,425,000 | $-49,367,000 |
| Operating Activities | ||||
| Operating Cash Flow | $-82,235,000 | $-43,814,000 | $-50,575,000 | $-42,922,000 |
| Cash Flow From Continuing Operating Activities | $-82,235,000 | $-43,814,000 | $-50,575,000 | $-42,922,000 |
| Operating Gains Losses | - | - | - | - |
| Investing Activities | ||||
| Capital Expenditure | $-1,043,000 | $-359,000 | $-1,850,000 | $-6,445,000 |
| Investing Cash Flow | $-300,981,000 | $-258,021,000 | $-41,194,000 | $58,266,000 |
| Cash Flow From Continuing Investing Activities | $-300,981,000 | $-258,021,000 | $-41,194,000 | $58,266,000 |
| Financing Activities | ||||
| Repurchase Of Capital Stock | $-347,000 | - | - | - |
| Financing Cash Flow | $4,945,000 | $713,235,000 | $59,548,000 | $500,000 |
| Cash Flow From Continuing Financing Activities | $4,945,000 | $713,235,000 | $59,548,000 | $500,000 |
| Net Common Stock Issuance | $-347,000 | $698,267,000 | $56,530,000 | $0 |
| Issuance Of Capital Stock | - | $698,267,000 | $56,530,000 | $0 |
| Common Stock Issuance | - | $698,267,000 | $56,530,000 | $0 |
| Net Preferred Stock Issuance | - | - | - | $0 |
| Preferred Stock Issuance | - | - | - | $0 |
| Other | ||||
| End Cash Position | $53,150,000 | $431,421,000 | $20,021,000 | $52,242,000 |
| Beginning Cash Position | $431,421,000 | $20,021,000 | $52,242,000 | $36,398,000 |
| Changes In Cash | $-378,271,000 | $411,400,000 | $-32,221,000 | $15,844,000 |
| Proceeds From Stock Option Exercised | $5,292,000 | $14,968,000 | $3,018,000 | $500,000 |
| Common Stock Payments | $-347,000 | - | - | - |
| Net Investment Purchase And Sale | $-299,938,000 | $-257,662,000 | $-39,344,000 | $64,711,000 |
| Sale Of Investment | $405,284,000 | $212,915,000 | $278,000,000 | $359,100,000 |
| Purchase Of Investment | $-705,222,000 | $-470,577,000 | $-317,344,000 | $-294,389,000 |
| Net PPE Purchase And Sale | $-1,043,000 | $-359,000 | $-1,850,000 | $-6,445,000 |
| Purchase Of PPE | $-1,043,000 | $-359,000 | $-1,850,000 | $-6,445,000 |
| Change In Working Capital | $6,714,000 | $685,000 | $-6,554,000 | $4,276,000 |
| Change In Other Working Capital | $-2,000 | $-1,670,000 | $-5,244,000 | $5,053,000 |
| Change In Other Current Assets | $276,000 | $-375,000 | $-1,119,000 | $-1,270,000 |
| Change In Payables And Accrued Expense | $7,267,000 | $6,010,000 | $-401,000 | $3,862,000 |
| Change In Accrued Expense | $6,290,000 | $4,426,000 | $-678,000 | $4,156,000 |
| Change In Payable | $977,000 | $1,584,000 | $277,000 | $-294,000 |
| Change In Account Payable | $977,000 | $1,584,000 | $277,000 | $-294,000 |
| Change In Prepaid Assets | $-827,000 | $-3,280,000 | $210,000 | $-3,369,000 |
| Stock Based Compensation | $40,221,000 | $33,020,000 | $20,005,000 | $17,203,000 |
| Amortization Of Securities | $-17,574,000 | $-10,585,000 | $-7,688,000 | $-2,183,000 |
| Depreciation Amortization Depletion | $2,029,000 | $2,060,000 | $1,955,000 | $841,000 |
| Depreciation And Amortization | $2,029,000 | $2,060,000 | $1,955,000 | $841,000 |
| Depreciation | $2,029,000 | $2,060,000 | $1,955,000 | $841,000 |
| Net Income From Continuing Operations | $-113,625,000 | $-68,994,000 | $-58,293,000 | $-63,059,000 |
| Change In Receivables | - | - | - | $0 |
| Changes In Account Receivables | - | - | - | $0 |
| Issuance Of Debt | - | - | - | - |
| Net Issuance Payments Of Debt | - | - | - | - |
| Net Long Term Debt Issuance | - | - | - | - |
| Long Term Debt Issuance | - | - | - | - |
Fetched: 2026-08-31